Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with stage II or stage III non-small cell lung cancer (a specific type of lung cancer), confirmed through tissue or cell testing and clinical assessment.
• People whose lung cancer has been determined by the doctor to be unable to be removed by surgery, either because of the tumour's location or because surgery is not safe for them medically.
• People who have definitive radiation therapy for lung cancer that is either planned to begin within the next 28 days, currently underway, or completed within the last 14 days (at a dose range specified in the trial).
• People who have received, are receiving, or are planned to receive platinum-based chemotherapy (a specific type of chemotherapy) for at least two cycles, either before or during radiation therapy, within similar timeframes.
• People for whom a follow-up treatment called durvalumab is planned after completing radiation and chemotherapy.
• People aged 18 or older.
• People with a general health and activity level rated 0–2 on a standard medical scale (meaning they are able to care for themselves, though they may have some limitations) (confirm with trial site).
• People with a life expectancy of more than three months.
• People who are sexually active with a partner who could become pregnant must be willing to use contraception during the study treatment period.
• People who are able to understand and willing to sign a formal consent document, either themselves or through a legally authorised representative.

Who may not be able to join:

• People with uncontrolled breathing or chest symptoms — such as coughing, shortness of breath, fevers, chest pain, or a new or increased need for oxygen — that are interfering with everyday activities.
• People whose lung cancer has been found to have a specific gene change (called an EGFR mutation, specifically Ex19del or L858R) that responds to a particular type of targeted drug treatment. Testing for this gene change must have been attempted before enrolment; however, if results are inconclusive and the treating doctor considers the mutation unlikely to be present, the person may still be eligible (confirm with trial site).
• People who have previously been treated with a type of cancer immunotherapy known as an immune checkpoint inhibitor targeting CTLA-4, PD-1, or PD-L1.
• People who have an active autoimmune disease (where the immune system attacks the body) that currently requires ongoing medication to suppress the immune system.
• People with a history of autoimmune-related lung inflammation that required high doses of steroid medication (above a specified threshold) for more than one week.
• People with other serious uncontrolled health conditions, such as an active infection, certain heart conditions, or mental health or social circumstances that would make it difficult to follow the study requirements.
• People who are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.